Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

26.48 -5.70 (-17.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
From Cassava Sciences, Inc.
Via GlobeNewswire
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla?
GameStop, SoFi, Tesla, Cassava Sciences and Anavex Life Sciences are the top five trending stocks on Stocktwits Friday. Here's a look at what's going on: 
Via Benzinga
Cassava Sciences Reports Q3 2024 Financial and Operating Results
From Cassava Sciences, Inc.
Via GlobeNewswire
Unpacking the Latest Options Trading Trends in Cassava Sciences
Via Benzinga
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Conference call and webcast to begin at 8:30 AM ET 
From Cassava Sciences, Inc.
Via GlobeNewswire
How Is The Market Feeling About Cassava Sciences?
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 Today
Via Benzinga
Analysts Believe Cassava Sciences Now Has 300% Upside From Here
Cassava Sciences faces controversy over its Alzheimer's drug, simufilam, amid fraud allegations, yet analysts maintain a Buy rating with high upside potential. 
Via MarketBeat
Topics Fraud Lawsuit
Exposures Criminal Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
Via Benzinga
Exposures Fossil Fuels
What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?
Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The firm anticipates top-line results from the ReTHINK Phase 3 trial before... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Cassava Sciences Unusual Options Activity
Via Benzinga
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Cassava Sciences Stock Dived by Almost 11% Today
Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive. 
Via The Motley Fool
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
Cassava Sciences and its executives face a $40 million SEC settlement over manipulated data in an Alzheimer's drug trial, misleading investors with false claims of cognitive improvement and selective... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cassava Sciences Resolves SEC Investigation
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials
Cassava Sciences, Inc. (NASDAQ: SAVA) shares trading higher following the announcement of a positive interim safety review of its Alzheimer's drug candidate, simufilam. Here's what you need to know. 
Via Benzinga
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Names Rick Barry as Chief Executive Officer
Claude Nicaise, M.D. appointed Chairman of the Board 
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Cassava Sciences has become a hot topic among traders due to its recent surge in volatility, liquidity, and overall market performance. 
Via MarketBeat
SAVA Stock Earnings: Cassava Sciences Beats EPS for Q2 2024
SAVA stock results show that Cassava Sciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.